Polycystic Ovarian Syndrome Treatment Market

Polycystic Ovarian Syndrome Treatment Market Outlook 2031

The Polycystic Ovarian Syndrome Treatment Market was USD 3.53 Billion in 2022 and is likely to reach USD 5.77 Billion by 2031, expanding at a CAGR of 5.61% during 2023 – 2031. The growth of the market is attributed to the increasing demand for polycystic syndrome (PCOS) treatment drugs across world and rising cases of PCOS in the market.

Get Free Sample Report

Polycystic ovarian syndrome is a hormonal condition that affects women of childbearing age and is marked by the production of cysts on the ovaries. It is associated with hirsutism, obesity, diabetes, and infertility, hence it requires proper treatment. At present, there is no particular cure for PCOS; however, it can be treated with drugs such as anti-androgens, anti-obesity, antidepressant, oral contraceptives, and insulin-sensitizing agent.

The COVID-19 pandemic has had an impact on certain surgical procedures such as laparoscopic ovarian drilling. In May 2020, University of Birmingham Experts at the University of Birmingham-led NIHR Global Research Health Unit on Global Surgery published their findings that the patients undergoing surgery after contracting coronavirus were at increased risk of postoperative death and were recommended to avoid all non-emergent surgeries.

The report further stated that patients who had contracted coronavirus and had surgery were on higher risk of mortality post-surgery and should avoid all non-emergent surgeries. However, in order to maintain normal surgical practices, regulatory authorities established a few guidelines unique to each profession that surgeons must implement and follow so as to continue to provide safe and effective care to their patients throughout the COVID-19 pandemic.

Polycystic Ovarian Syndrome Treatment Market Trends, Drivers, Restraints, and Opportunities

• Ongoing R&D activities and investment by key players in developing innovative and improved treatment devices with better safety and efficacy are expected to propel the market growth in the coming years.
• Rising in genetic and hormonal diseases in growing population is a key factor propelling the market growth.
• Delaying drugs approval by regulatory bodies such as the US Food and Drug Administration (FDA) in the US and other regulators among many countries present key factors hampering the growth of the market.
• Various side effects of drugs in the treatment procedure is expected to hamper the market growth.
• Several initiatives undertaken by government bodies in order to increase awareness about disorders among people are offering good opportunity to fuel the growth of the market in near future.

Scope of Polycystic Ovarian Syndrome Treatment Report

The report on the global polycystic ovarian syndrome treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Polycystic Ovarian Syndrome Treatment  Market Segment Insights

Insulin- sensitizing agent segment is expected to register a key market share

Based on drugs, the global polycystic ovarian syndrome treatment market is segregated as antiandrogens, anti-obesity, antidepressant, oral contraceptives, and insulin-sensitizing agent. The insulin- sensitizing agent segment is expected to register a key market share during the forecast period. Various products containing Rosiglitazone, Troglitazone, and Pioglitazone are widely available in the market including Glucophage XR (Metformin) for the treatment of polycystic ovarian syndrome.

Metabolic dysfunction in PCOS can lead to an increase in androgen secretion, which can influence insulin secretion and raise the risk of diabetes. Therefore, insulin-sensitizing drugs play an essential function in therapies as they lower insulin levels and reduce ovarian androgen production as well as balancing hormone levels.

Meanwhile, the oral contraceptive (OCPs) pills segment is also expected to upsurge in the market during the projected period due to the wide availability of oral contraceptive products such as Drospirenone, Ethinyl Estradiol, and Medroxyprogesterone Acetate. Severe menstrual pain, irregular menstrual cycle, acne, and premenstrual syndrome are common indicators of PCOS that are treated by using OCPs. Thus, the demand for OCPs segment is increasing, which further boost the segment growth.

Get Free Sample Report

Laparoscopic ovarian drilling segment is projected to expand substantially

On the basis of surgery, the market is bifurcated into laparoscopic ovarian drilling and ovarian wedge resection. The laparoscopic ovarian drilling segment is projected to expand substantially in the market in the coming years as it is commonly recommended by doctors in critical conditions. Due to the increasing cases of PCOS that causes infertility in women, the effect of medication decrease over time.

Thus, surgery with the help of thin microscope through the belly is highly recommended and undertaken by specialist all over the world.  Furthermore, patients are recommended to this surgical technique since it is affordable and allows them to address their ailment quickly. Thus, it is expected to have a sizable market share during the forecast period.

Get Free Sample Report

North America is anticipated to constitute a key market share

In terms of regions, the global polycystic ovarian syndrome treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period. The growth of the market attributed to the increasing cases of overweight & obesity, further leads to increasing incidence of PCOS patient. In terms of procurement of advanced technology and early drugs released, the US and Canada have first move advantage in the market. Moreover, major players have strong base along with strong product portfolio in the region.

For example, an oral gonadotropin-releasing hormone antagonist, Elagolix (ABT-620) is being researched by AbbVie, a US-based business for the treatment of endometriosis and PCOS. The University of Illinois at Chicago funded clinical research has conducted the research in November 2019, to examine the effect of salsalate administration on insulin sensitivity and on the ovarian capacity to conceal androgen in PCOS.

Get Free Sample Report

Segments

The global polycystic ovarian syndrome treatment market has been segmented on the basis of

Drugs

• Antiandrogens
• Anti-obesity
• Antidepressant
• Oral Contraceptives
• Insulin-sensitizing Agent

Surgery

• Laparoscopic Ovarian Drilling
• Ovarian Wedge Resection

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Abbott
• Bayer AG
• Sanofi
• Merck KGaA
• Pfizer, Inc.
• Bristol-Myer Squibb Co.
• Novartis AG
• AstraZeneca

Competitive Landscape

Some of the major players competing in the market are Abbott; Bayer AG; Sanofi; Merck KGaA; Pfizer, Inc.; Bristol-Myer Squibb Co; Novartis AG.; and AstraZeneca. These major players are implementing various marketing strategies such as capital investments, merger & acquisitions, and new product development to enhance their market position in the regional competition.

Bayer AG, and Evotec SE have launched a new five-year in January 2020, multi-target partnership with Celmatix Inc. for the development of numerous clinical candidates for the treatment of PCOS. Thus, it is projected to propel the market during the forecast period. Abbvie declared its ongoing clinical trial using the chemical Elagolix in January 2020, which was being examined for its safety and efficacy in women with polycystic ovarian syndrome. The business has conducted a Phase 2 multicenter, double-blind, randomized, and placebo-controlled research to evaluate Elagolix's efficiency of polycystic ovarian syndrome.